IL162330A0 - Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) - Google Patents

Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Info

Publication number: IL162330A0
Authority: IL; Israel
Prior art keywords: ppar; agonists; acid derivatives; activated receptor; receptor alpha
Prior art date: 2001-12-19

Application number

IL16233002A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2002-12-18

Publication date

2005-11-20

2002-12-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-11-20 Publication of IL162330A0 publication Critical patent/IL162330A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16233002A 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) IL162330A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0104334A SE0104334D0 (sv)	2001-12-19	2001-12-19	Therapeutic agents
PCT/GB2002/005738 WO2003051821A1 (en)	2001-12-19	2002-12-18	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Publications (1)

Publication Number	Publication Date
IL162330A0 true IL162330A0 (en)	2005-11-20

Family

ID=20286433

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL16233102A IL162331A0 (en)	2001-12-19	2002-12-18	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
IL16233002A IL162330A0 (en)	2001-12-19	2002-12-18	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
IL162330A IL162330A (en)	2001-12-19	2004-06-03	Substituted phenylpropionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of lipid disorders (dyslipidemias), whether or not associated with insulin resistance

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IL16233102A IL162331A0 (en)	2001-12-19	2002-12-18	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL162330A IL162330A (en)	2001-12-19	2004-06-03	Substituted phenylpropionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of lipid disorders (dyslipidemias), whether or not associated with insulin resistance

Country Status (30)

Country	Link
US (2)	US7256307B2 (es)
EP (2)	EP1458672B1 (es)
JP (4)	JP3820249B2 (es)
KR (2)	KR20040074092A (es)
CN (3)	CN1293044C (es)
AR (2)	AR038045A1 (es)
AT (2)	ATE338743T1 (es)
AU (2)	AU2002366315A1 (es)
BR (2)	BR0214986A (es)
CA (2)	CA2470491A1 (es)
CY (2)	CY1106276T1 (es)
DE (2)	DE60214594T2 (es)
DK (2)	DK1458672T3 (es)
ES (2)	ES2286310T3 (es)
HU (2)	HUP0402022A3 (es)
IL (3)	IL162331A0 (es)
IS (2)	IS7309A (es)
MX (2)	MXPA04006004A (es)
MY (1)	MY132565A (es)
NO (2)	NO20043023L (es)
NZ (2)	NZ533274A (es)
PL (2)	PL370672A1 (es)
PT (2)	PT1458673E (es)
RU (2)	RU2300517C2 (es)
SE (1)	SE0104334D0 (es)
SI (2)	SI1458673T1 (es)
TW (2)	TWI253444B (es)
UA (2)	UA77987C2 (es)
WO (2)	WO2003051821A1 (es)
ZA (2)	ZA200404657B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1350521A (zh)	1999-03-05	2002-05-22	宝洁公司	C16不饱和的fp选择性前列腺素类似物
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
SE0104334D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0229931D0 (en) *	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0314079D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
SE0104333D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
BR0311834A (pt) *	2002-06-19	2005-04-12	Lilly Co Eli	Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
CN1319938C (zh)	2002-06-20	2007-06-06	阿斯特拉曾尼卡有限公司	治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
ES2295816T3 (es)	2003-01-14	2008-04-16	Arena Pharmaceuticals, Inc.	Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0314129D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314134D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314136D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1722780A4 (en) *	2003-11-26	2008-12-17	Univ Duke	METHOD FOR PREVENTING OR TREATING GLAUCOMA
CA2549008A1 (en) *	2003-12-15	2005-07-07	Eli Lilly And Company	Selective peroxisome proliferator activated receptor modulators
CN101014595A (zh)	2004-08-11	2007-08-08	杏林制药株式会社	新型环状氨基苯甲酸衍生物
SE0403072D0 (sv) *	2004-12-16	2004-12-16	Astrazeneca Ab	Pharmaceutically useful salts of carboxylic acid derivates
CA2610354C (en)	2005-05-31	2011-03-29	Pfizer Inc.	Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007004957A1 (en) *	2005-07-05	2007-01-11	Astrazeneca Ab	Novel crystalline form
AR055073A1 (es) *	2005-07-11	2007-08-01	Astrazeneca Ab	Agentes terapeuticos
TWI331523B (en) *	2005-12-08	2010-10-11	Nat Health Research Institutes	Vinylsulfonate compounds
CN101054372B (zh) *	2006-04-11	2010-10-13	中国科学院上海药物研究所	嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
KR100847780B1 (ko) *	2006-10-26	2008-07-23	재단법인서울대학교산학협력재단	2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
RU2361581C2 (ru)	2007-09-14	2009-07-20	Закрытое Акционерное Общество "Мастерклон"	Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
US20110293549A1 (en)	2009-02-03	2011-12-01	Athena Cosmetics, Inc.	Composition, method and kit for enhancing hair
EP2619198A1 (en)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2815749C (en)	2010-11-04	2019-12-03	Albireo Ab	Ibat inhibitors for the treatment of liver diseases
JO3301B1 (ar) *	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja)	2014-06-25	2020-09-02	Ｅａファーマ株式会社	固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CA3071285A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202015699A (zh)	2018-06-05	2020-05-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
WO2019245448A1 (en)	2018-06-20	2019-12-26	Albireo Ab	Crystal modifications of odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
MX2021008981A (es)	2019-02-06	2021-09-08	Albireo Ab	Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (zh)	2019-12-04	2025-12-02	阿尔比里奥公司	苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
BR112022010505A2 (pt)	2019-12-04	2022-09-06	Albireo Ab	Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh)	2019-12-04	2024-07-23	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja)	2020-11-12	2023-11-22	アルビレオエービー	進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
WO2022117778A1 (en)	2020-12-04	2022-06-09	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023039276A1 (en) *	2021-09-13	2023-03-16	Curtails Llc	Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE266121C (es)
BE489216A (es)	1948-06-05	1900-01-01
US2928840A (en) *	1958-11-26	1960-03-15	Us Vitamin Pharm Corp	3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en)	1963-09-13	1967-08-31	Stauffer Chemical Co	Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) *	1963-10-28	1966-04-05	Scaramucci Domer	Composite seat ball valve
AT307640B (de)	1970-06-18	1973-05-25	Richter Gedeon Vegyeszet	Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr)	1971-12-06	1973-06-06	Basf Ag	Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de)	1973-10-01	1985-08-01	Basf Ag, 6700 Ludwigshafen	0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de)	1978-06-28	1980-01-10	Bayer Ag	Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) *	1981-01-10	1988-04-05	Dr. Karl Thomae Gmbh	Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) *	1983-12-30	1994-05-17	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
US5216167A (en) *	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
US5210208A (en)	1990-09-24	1993-05-11	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en)	1995-06-07	1999-09-28	Chiron Corporation	Combinatorial libraries of substrate-bound cyclic organic compounds
DE69824433D1 (en)	1997-08-28	2004-07-15	Biovitrum Ab	Proteintyrosinphosphatase inhibitoren
US6410585B1 (en) *	1997-08-28	2002-06-25	Scott D. Larsen	Inhibitors of protein tyrosine phosphatase
CA2309792A1 (en)	1997-11-12	1999-05-20	William C. Shakespeare	Novel signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) *	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
KR20020060067A (ko) *	1999-04-06	2002-07-16	가와무라 요시부미	α-치환 카르복실산 유도체
WO2000061582A1 (en) *	1999-04-08	2000-10-19	Sankyo Company, Limited	Substituted fused imidazole derivatives
WO2000061585A2 (en)	1999-04-14	2000-10-19	The University Of British Columbia (Ubc)	1,3-dipolar cycloadditions to polypyrrolic macrocycles
AU3958200A (en)	1999-04-20	2000-11-02	Novo Nordisk A/S	New compounds, their preparation and use
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
JP4618845B2 (ja) *	1999-06-09	2011-01-26	杏林製薬株式会社	ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) *	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) *	2000-03-22	2001-09-26	Mitsui Chemicals Inc	カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
JPWO2002044130A1 (ja)	2000-11-29	2004-04-02	杏林製薬株式会社	置換カルボン酸誘導体
WO2002044127A1 (fr) *	2000-11-29	2002-06-06	Kyorin Pharmaceutical Co., Ltd.	Dérivés d'acide carboxylique substitué
WO2002064549A1 (en)	2001-02-15	2002-08-22	Pfizer Products Inc.	Ppar agonists
WO2002083616A1 (en) *	2001-04-10	2002-10-24	Sankyo Company, Limited	α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
SE0104334D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0314079D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
BR0311834A (pt)	2002-06-19	2005-04-12	Lilly Co Eli	Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
GB0314134D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314129D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314136D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents

2001
- 2001-12-19 SE SE0104334A patent/SE0104334D0/xx unknown
2002
- 2002-12-18 EP EP02788145A patent/EP1458672B1/en not_active Expired - Lifetime
- 2002-12-18 AT AT02804964T patent/ATE338743T1/de not_active IP Right Cessation
- 2002-12-18 IL IL16233102A patent/IL162331A0/xx unknown
- 2002-12-18 HU HU0402022A patent/HUP0402022A3/hu unknown
- 2002-12-18 ES ES02788145T patent/ES2286310T3/es not_active Expired - Lifetime
- 2002-12-18 TW TW091136518A patent/TWI253444B/zh not_active IP Right Cessation
- 2002-12-18 EP EP02804964A patent/EP1458673B1/en not_active Expired - Lifetime
- 2002-12-18 PT PT02804964T patent/PT1458673E/pt unknown
- 2002-12-18 MX MXPA04006004A patent/MXPA04006004A/es active IP Right Grant
- 2002-12-18 KR KR10-2004-7009501A patent/KR20040074092A/ko not_active Withdrawn
- 2002-12-18 CA CA002470491A patent/CA2470491A1/en not_active Abandoned
- 2002-12-18 US US10/499,378 patent/US7256307B2/en not_active Expired - Fee Related
- 2002-12-18 DK DK02788145T patent/DK1458672T3/da active
- 2002-12-18 RU RU2004116918/04A patent/RU2300517C2/ru not_active IP Right Cessation
- 2002-12-18 PT PT02788145T patent/PT1458672E/pt unknown
- 2002-12-18 AU AU2002366315A patent/AU2002366315A1/en not_active Abandoned
- 2002-12-18 PL PL02370672A patent/PL370672A1/xx not_active Application Discontinuation
- 2002-12-18 DK DK02804964T patent/DK1458673T3/da active
- 2002-12-18 US US10/499,261 patent/US7514471B2/en not_active Expired - Fee Related
- 2002-12-18 HU HU0402133A patent/HUP0402133A3/hu unknown
- 2002-12-18 CN CNB028281233A patent/CN1293044C/zh not_active Expired - Fee Related
- 2002-12-18 BR BR0214986-9A patent/BR0214986A/pt not_active IP Right Cessation
- 2002-12-18 BR BR0214988-5A patent/BR0214988A/pt not_active IP Right Cessation
- 2002-12-18 JP JP2003552710A patent/JP3820249B2/ja not_active Expired - Lifetime
- 2002-12-18 IL IL16233002A patent/IL162330A0/xx unknown
- 2002-12-18 NZ NZ533274A patent/NZ533274A/en unknown
- 2002-12-18 CN CNB2006100071731A patent/CN100406427C/zh not_active Expired - Fee Related
- 2002-12-18 AT AT02788145T patent/ATE363466T1/de not_active IP Right Cessation
- 2002-12-18 DE DE60214594T patent/DE60214594T2/de not_active Expired - Lifetime
- 2002-12-18 MY MYPI20024740A patent/MY132565A/en unknown
- 2002-12-18 JP JP2003552709A patent/JP3784804B2/ja not_active Expired - Fee Related
- 2002-12-18 WO PCT/GB2002/005738 patent/WO2003051821A1/en not_active Ceased
- 2002-12-18 NZ NZ533276A patent/NZ533276A/en unknown
- 2002-12-18 SI SI200230424T patent/SI1458673T1/sl unknown
- 2002-12-18 AU AU2002352427A patent/AU2002352427A1/en not_active Abandoned
- 2002-12-18 RU RU2004116917/04A patent/RU2303031C2/ru not_active IP Right Cessation
- 2002-12-18 CA CA002469302A patent/CA2469302A1/en not_active Abandoned
- 2002-12-18 UA UA20040604245A patent/UA77987C2/uk unknown
- 2002-12-18 UA UA20040604246A patent/UA77460C2/uk unknown
- 2002-12-18 CN CNA028281551A patent/CN1620423A/zh active Pending
- 2002-12-18 SI SI200230570T patent/SI1458672T1/sl unknown
- 2002-12-18 KR KR10-2004-7009517A patent/KR20040074094A/ko not_active Ceased
- 2002-12-18 DE DE60220441T patent/DE60220441T2/de not_active Expired - Fee Related
- 2002-12-18 ES ES02804964T patent/ES2271381T3/es not_active Expired - Lifetime
- 2002-12-18 PL PL02370673A patent/PL370673A1/xx not_active Application Discontinuation
- 2002-12-18 WO PCT/GB2002/005744 patent/WO2003051822A1/en not_active Ceased
- 2002-12-18 TW TW091136519A patent/TWI255807B/zh not_active IP Right Cessation
- 2002-12-18 MX MXPA04006003A patent/MXPA04006003A/es active IP Right Grant
- 2002-12-19 AR ARP020105002A patent/AR038045A1/es unknown
- 2002-12-19 AR ARP020105004A patent/AR038047A1/es not_active Application Discontinuation
2004
- 2004-06-03 IL IL162330A patent/IL162330A/en not_active IP Right Cessation
- 2004-06-11 ZA ZA200404657A patent/ZA200404657B/en unknown
- 2004-06-11 ZA ZA200404658A patent/ZA200404658B/en unknown
- 2004-06-14 IS IS7309A patent/IS7309A/is unknown
- 2004-06-15 IS IS7313A patent/IS7313A/is unknown
- 2004-07-15 NO NO20043023A patent/NO20043023L/no not_active Application Discontinuation
- 2004-07-16 NO NO20043164A patent/NO20043164L/no not_active Application Discontinuation
2005
- 2005-08-16 JP JP2005235794A patent/JP2005336209A/ja active Pending
2006
- 2006-04-27 JP JP2006123399A patent/JP2006298924A/ja active Pending
- 2006-12-05 CY CY20061101743T patent/CY1106276T1/el unknown
2007
- 2007-08-01 CY CY20071101028T patent/CY1106784T1/el unknown

Also Published As

Publication number	Publication date
IL162330A (en)	2009-06-15
US7256307B2 (en)	2007-08-14
CN1896045A (zh)	2007-01-17
NZ533276A (en)	2006-04-28
WO2003051821A1 (en)	2003-06-26
RU2004116917A (ru)	2005-11-10
ES2286310T3 (es)	2007-12-01
TWI255807B (en)	2006-06-01
PL370673A1 (en)	2005-05-30
TW200410918A (en)	2004-07-01
AR038045A1 (es)	2004-12-22
DE60214594T2 (de)	2007-09-13
AU2002366315A1 (en)	2003-06-30
NZ533274A (en)	2005-12-23
US20050113362A1 (en)	2005-05-26
RU2300517C2 (ru)	2007-06-10
IS7313A (is)	2004-06-15
HK1068604A1 (en)	2005-04-29
EP1458673A1 (en)	2004-09-22
CY1106276T1 (el)	2011-10-12
JP2006298924A (ja)	2006-11-02
SI1458672T1 (sl)	2007-10-31
CN1620422A (zh)	2005-05-25
CN100406427C (zh)	2008-07-30
PL370672A1 (en)	2005-05-30
ATE338743T1 (de)	2006-09-15
CA2470491A1 (en)	2003-06-26
CA2469302A1 (en)	2003-06-26
DE60220441T2 (de)	2008-01-24
SI1458673T1 (sl)	2007-02-28
WO2003051822A1 (en)	2003-06-26
IS7309A (is)	2004-06-14
EP1458673B1 (en)	2006-09-06
HUP0402022A2 (hu)	2005-01-28
TW200410925A (en)	2004-07-01
KR20040074094A (ko)	2004-08-21
US20050171204A1 (en)	2005-08-04
DE60214594D1 (de)	2006-10-19
EP1458672B1 (en)	2007-05-30
JP2005336209A (ja)	2005-12-08
HUP0402133A3 (en)	2010-07-28
JP3820249B2 (ja)	2006-09-13
SE0104334D0 (sv)	2001-12-19
US7514471B2 (en)	2009-04-07
MXPA04006003A (es)	2004-09-27
JP2005526011A (ja)	2005-09-02
NO20043164L (no)	2004-07-16
JP2005526704A (ja)	2005-09-08
ZA200404657B (en)	2005-08-29
UA77460C2 (en)	2006-12-15
IL162331A0 (en)	2005-11-20
KR20040074092A (ko)	2004-08-21
AR038047A1 (es)	2004-12-22
HUP0402022A3 (en)	2009-06-29
DE60220441D1 (de)	2007-07-12
CN1293044C (zh)	2007-01-03
CY1106784T1 (el)	2012-05-23
ATE363466T1 (de)	2007-06-15
MXPA04006004A (es)	2004-09-27
RU2303031C2 (ru)	2007-07-20
PT1458673E (pt)	2006-12-29
JP3784804B2 (ja)	2006-06-14
BR0214988A (pt)	2004-12-14
BR0214986A (pt)	2004-12-14
AU2002352427A1 (en)	2003-06-30
EP1458672A1 (en)	2004-09-22
ZA200404658B (en)	2006-02-22
RU2004116918A (ru)	2005-11-10
CN1620423A (zh)	2005-05-25
UA77987C2 (en)	2007-02-15
NO20043023L (no)	2004-07-15
DK1458672T3 (da)	2007-09-17
TWI253444B (en)	2006-04-21
MY132565A (en)	2007-10-31
HUP0402133A2 (hu)	2005-02-28
DK1458673T3 (da)	2006-12-11
HK1068870A1 (en)	2005-05-06
PT1458672E (pt)	2007-07-18
ES2271381T3 (es)	2007-04-16

Publication	Publication Date	Title
IL162330A0 (en)	2005-11-20	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
HUP0201654A3 (en)	2004-03-01	Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) alpha, their preparation and pharmaceutical composition containing the same
NO20032059D0 (no)	2003-05-08	Peroksisomprolferatoraktiverte reseptoralfa-agonister
IL147821A0 (en)	2002-08-14	Benzoic acid derivatives and their use as ppar receptor agonists
ID30502A (id)	2001-12-13	Senyawa heteroaromatik bisiklik yang berguna sebagai agonis lh
IL159025A0 (en)	2004-05-12	Hydrophobic dopamine agonists administered to the dermis
AU7191001A (en)	2002-01-30	Use of dopamine D<sub>2</sub>/D<sub>3</sub> receptor agonists to treat fibromyalgia
IL175310A0 (en)	2006-09-05	Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
MXPA04000891A (es)	2004-05-21	Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
IL161578A0 (en)	2004-09-27	Peroxisome proliferator activated receptor agonists
EP1397150A4 (en)	2005-01-26	Somatostatin agonists
HUP0300857A3 (en)	2007-03-28	Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
NO20031517D0 (no)	2003-04-03	Propionsyrederivater med PPAR-alfa aktiverende egenskaper
SI1551814T1 (sl)	2008-10-31	Derivati kiralne oksazol-arilpropionske kisline in njihova uporaba kot ppar-agonisti
SI1539746T1 (sl)	2007-04-30	Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
AU2002347985A1 (en)	2003-06-10	Peroxisome proliferator activated receptor alpha agonists
DE60142038D1 (de)	2010-06-17	Aktivatoren des peroxisome proliferator-activated rezeptors
AU2003255893A1 (en)	2004-03-29	USE OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR $f(a)) AGONIST FOR THE TREATMENT OF CARNITINE PALMITOYL TRANSFERASE-2 DEFICIENCIES
HK1057041A (en)	2004-03-12	Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
HK1071563A (en)	2005-07-22	Peroxisome proliferator activated receptor agonists